Table 1.
Clinical information for control and MDS/AML patients
| Patient ID | Sex | FAB | Cytogenetics | WBC (×1000) | PB blast (%) | BM blast (%) |
|---|---|---|---|---|---|---|
| Normal controls | ||||||
| C1 | M | Normal | Normal | 11.8 | 0 | 1 |
| C2 | F | Normal | Normal | 7.4 | 0 | 1 |
| C3 | F | Normal | Normal | 2.6 | 0 | 3 |
| MDS | ||||||
| M3 | M | RAEB | NA | 7.9 | NA | 12 |
| M5 | M | RAEB | NA | 1.8 | NA | 13 |
| M7 | M | RAEB | Normal | 6.9 | 0 | 6 |
| M8 | M | RAEBT | NA | NA | NA | 8 |
| M36 | M | RA | 45,XY,−7,(2p-;3q +) | 19.6 | 17 | 18.8 |
| M37 | F | RAEBT | 45,XX, −7 | NA | NA | NA |
| M39 | F | RAEBT | 46,XX, −7, + 8; 47–48,XX, −7, 8, + mar[cp3]; 46,XX | 10.5 | 18 | 22 |
| M40 | M | RAEB | 45,XY, −7; 46,XY, −7,mar[cp4]; 46,XY | 3.6 | 2 | 12 |
| M41 | F | RAEBT | 46,idem, −7, + mar[2]; 47,idem with random changes | 8.4 | 7 | 16 |
| AML | ||||||
| A6 | M | M1 | 46,XY,del(9)(q12q22)[5]; 46,XY,del(9)(q12q22), −21, + mar[2]; 46,XY[13] | 10.6 | 81 | 83 |
| A7 | F | M1 | Normal | 64.3 | 98 | 93 |
| A8 | F | M2 | Normal | 45.8 | 66 | 63 |
| A9 | M | M2 | 46,XY,t(6;9)(p23;q34)[16]; 46,XY[2] | 10.7 | 45 | 62 |
| A10 | M | M1 | 45,XY,der(12)t(12;17)(p13;q11.2),−7[20] | 47.7 | 88 | 93 |
| A11 | M | M2 | 47,XY, + 21[14]; 46,XY[6] | 32 | 62 | 74 |
| A12 | M | M5 | 47,XY, + 8[15]; 46,XY[2] | 200.5 | 63 | 86 |
| A13 | M | M5 | Normal | 29.1 | 22 | 80 |
| A14 | M | M3 | 46,XY,del(7)(q22)[1] 43–47,XY,del(7)(q22),−8, −9, + 1–2r[cp18]; 46,XY[1] | 7.3 | 1 | 60 |
| A15 | M | M3 | 46,XY,t(15;17)(q22;q21)[10]; 45,XY,del(1)(q23),del(3)(p11),−6,t(15;17)(q22;q21),add(19)(q13.4)[10] | 1.4 | 0 | 7 |
Abbreviations: BM, bone marrow; F, female; FAB, French-American-British classification for hematologic diseases; M, male; MDS, myelodysplastic syndrome; NA, not available; PB, peripheral blood; RA, refractory anemia; RAEB, refractory anemia with excess blasts; RAEBT, refractory anemia with excess blasts in transformation; WBC, white blood cell.